- Home
- EPAM vs CORT Comparison
EPAM vs CORT Comparison
Compare EPAM & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPAM
- CORT
- Stock Information
- Founded
- EPAM 1993
- CORT 1998
- Country
- EPAM United States
- CORT United States
- Employees
- EPAM N/A
- CORT N/A
- Industry
- EPAM EDP Services
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- EPAM Technology
- CORT Health Care
- Exchange
- EPAM Nasdaq
- CORT Nasdaq
- Market Cap
- EPAM 8.2B
- CORT 7.5B
- IPO Year
- EPAM 2012
- CORT N/A
- Fundamental
- Price
- EPAM $182.83
- CORT $72.98
- Analyst Decision
- EPAM Buy
- CORT Strong Buy
- Analyst Count
- EPAM 14
- CORT 4
- Target Price
- EPAM $231.43
- CORT $142.00
- AVG Volume (30 Days)
- EPAM 631.0K
- CORT 1.6M
- Earning Date
- EPAM 08-07-2025
- CORT 07-28-2025
- Dividend Yield
- EPAM N/A
- CORT N/A
- EPS Growth
- EPAM N/A
- CORT 8.36
- EPS
- EPAM 7.15
- CORT 1.14
- Revenue
- EPAM $4,864,167,000.00
- CORT $685,446,000.00
- Revenue This Year
- EPAM $15.44
- CORT $35.83
- Revenue Next Year
- EPAM $7.38
- CORT $35.24
- P/E Ratio
- EPAM $25.56
- CORT $63.26
- Revenue Growth
- EPAM 4.72
- CORT 30.93
- 52 Week Low
- EPAM $138.15
- CORT $29.42
- 52 Week High
- EPAM $269.00
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- EPAM 62.87
- CORT 49.68
- Support Level
- EPAM $158.54
- CORT $68.52
- Resistance Level
- EPAM $183.04
- CORT $75.95
- Average True Range (ATR)
- EPAM 4.35
- CORT 2.66
- MACD
- EPAM 1.16
- CORT -0.13
- Stochastic Oscillator
- EPAM 98.58
- CORT 42.13
About EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm that offers platform engineering, software development, and consulting services. EPAM's largest market is North America, which represents approximately 60% of revenue. Offerings span assisting companies with new technologies, such as artificial intelligence, virtual reality, and robotics.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.